Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.38 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.33 |
| ▸ | CASP3 | P42574 | 2/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.33 |
| ▸ | PLAT | P00750 | 1/20 | 0.32 |
| ▸ | IDH1 | O75874 | 1/20 | 0.32 |
| ▸ | PDE2A | O00408 | 1/20 | 0.31 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.31 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.31 |
| ▸ | LIPE | Q05469 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4217197 | 0.91 | S1PR1 (0.39) | DPP4SCN10ADPP7S1PR1CASP3 | |
| SCHEMBL4233634 | 0.90 | DPP4 (0.39) | DPP4SCN10ADPP7S1PR1CASP3 | |
| SCHEMBL4219341 | 0.89 | RAB9A (0.39) | CASP3HDAC1HDAC6SENP8SENP7 | |
| SCHEMBL4227027 | 0.89 | CASP3 (0.39) | CASP3SENP8SENP7 | |
| SCHEMBL4229344 | 0.88 | NPC1 (0.34) | CASP3HDAC1HDAC6SENP8SENP7 | |
| SCHEMBL4226963 | 0.87 | DPP4 (0.39) | DPP4SCN10AOPRM1DPP7S1PR1 | |
| SCHEMBL4226968 | 0.87 | DPP4 (0.39) | DPP4SCN10AOPRM1DPP7S1PR1 | |
| SCHEMBL4226967 | 0.87 | DPP4 (0.39) | DPP4SCN10AOPRM1DPP7S1PR1 | |
| SCHEMBL4224763 | 0.86 | TP53 (0.38) | S1PR1 | |
| SCHEMBL4227522 | 0.85 | CASP3 (0.39) | DPP4SCN10ADPP7S1PR1CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1963289-B1 | SUBSTITUTED OXADIAZOLE DERIVATIVES AND THEIR USE AS OPIOID RECEPTOR LIGANDS | GRUENENTHAL GMBH (DE) | 2013-05-15 | — | — | EP | claimed |
| US-7589113-B2 | Substituted oxadiazole compounds and their use as opioid receptor ligands | GRUENENTHAL GMBH (DE) | 2009-09-15 | — | — | US | claimed |
| US-20090005427-A1 | SUBSTITUTED OXADIAZOLE COMPOUNDS AND THEIR USE AS OPIOID RECEPTOR LIGANDS | GRUENENTHAL GMBH (DE) | 2009-01-01 | — | — | US | claimed |
| EP-1963289-A1 | SUBSTITUTED OXADIAZOLE DERIVATIVES AND THEIR USE AS OPIOID RECEPTOR LIGANDS | Grünenthal GmbH (DE) | 2008-09-03 | — | — | EP | claimed |
| WO-2007079931-A1 | SUBSTITUTED OXADIAZOLE DERIVATIVES AND THEIR USE AS OPIOID RECEPTOR LIGANDS | Grünenthal GmbH (DE) | 2007-07-19 | — | — | WO | claimed |
| EP-1963289-B1 | SUBSTITUTED OXADIAZOLE DERIVATIVES AND THEIR USE AS OPIOID RECEPTOR LIGANDS | GRUENENTHAL GMBH (DE) | 2013-05-15 | — | — | EP | disclosed |
| US-7589113-B2 | Substituted oxadiazole compounds and their use as opioid receptor ligands | GRUENENTHAL GMBH (DE) | 2009-09-15 | — | — | US | disclosed |
| US-20090005427-A1 | SUBSTITUTED OXADIAZOLE COMPOUNDS AND THEIR USE AS OPIOID RECEPTOR LIGANDS | GRUENENTHAL GMBH (DE) | 2009-01-01 | — | — | US | disclosed |
| EP-1963289-A1 | SUBSTITUTED OXADIAZOLE DERIVATIVES AND THEIR USE AS OPIOID RECEPTOR LIGANDS | Grünenthal GmbH (DE) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007079931-A1 | SUBSTITUTED OXADIAZOLE DERIVATIVES AND THEIR USE AS OPIOID RECEPTOR LIGANDS | Grünenthal GmbH (DE) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005427-A1 | SUBSTITUTED OXADIAZOLE COMPOUNDS AND THEIR USE AS OPIOID RECEPTOR LIGANDS | OPRM1, OPRD1, OPRK1 | DPP4 4452/4885SCN10A 2110/4885OPRM1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.